AvalehtME • NASDAQ
add
23andMe Holding Co.
Viimane sulgemishind
0,49 $
Tänane vahemik
0,49 $ - 0,51 $
Aasta vahemik
0,35 $ - 2,03 $
Turuväärtus
246,24 mln USD
Keskmine maht
5,51 mln
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Käive | 64,03 mln | −30,69% |
Põhitegevusega seonduv kulu | 53,15 mln | −51,42% |
Puhastulu | −208,83 mln | −225,80% |
Puhaskasumimarginaal | −326,16 | −370,04% |
Puhaskasum aktsia kohta | −0,43 | −206,96% |
EBITDA | −22,06 mln | 64,57% |
Tõhus maksumäär | −0,01% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 216,49 mln | −44,04% |
Kogu vara | 395,17 mln | −58,08% |
Kõik kohustused | 206,65 mln | −9,63% |
Kogu omakapital | 188,52 mln | — |
Emiteeritud aktsiate arv | 490,26 mln | — |
Hinna ja väärtuse suhe P/B | 1,28 | — |
Varade tasuvus | −13,02% | — |
Kapitali tasuvus | −18,11% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | märts 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −208,83 mln | −225,80% |
Põhitegevuse rahakäive | −25,78 mln | 42,65% |
Investeeringute raha | −2,15 mln | 34,73% |
Finantseerimise raha | 2,00 mln | −23,25% |
Raha ja raha ekvivalentide muutus | −25,93 mln | 43,57% |
Tasuta rahavoog | 50,88 mln | 282,19% |
Teave
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Tegevjuht
Asutatud
apr 2006
Veebisait
Töötajate arv
571